What is Acro Biomedical Co Ltd's earnings per share (EPS)?

Acro Biomedical Co Ltd (ACBM) reported diluted earnings per share of $0.00 for fiscal year 2025. EPS represents the portion of a company's net income allocated to each outstanding share of common stock and is widely used to evaluate profitability on a per-share basis.

Acro Biomedical Co Ltd Financials

ACBM

Source SEC Filings (10-K/10-Q) Updated Mar 31, 2026 Currency USD FYE December

This page shows Acro Biomedical Co Ltd (ACBM) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 11 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).

Rhea AI ACBM FY2025 2026-05-05

Shrinking assets and externally funded overhead show a business now operating more for balance-sheet survival than for growth.

From FY2022 to FY2025, current assets fell from $658K to $14K. At the same time, liabilities kept rising and the current ratio slid from 3.3x to 0.04x, showing that balance-sheet shrinkage, not just recurring losses, erased the cushion that once financed day-to-day obligations.

In FY2021-FY2022, gross margin stayed near 21%, so the later strain was not explained by product economics alone. Accounts receivable reached $639K against $659K of FY2022 revenue, indicating that reported sales were becoming much less effective at turning into cash.

FY2024 operating cash burn of -$36.7K was almost entirely offset by financing inflow of $36.8K. With equity still at -$295K, outside funding appears to have covered basic overhead rather than repairing the balance sheet or restoring working-capital flexibility.

Financial Health Signals

Financial Profile 16/100

Based on FY2025 annual data, averaged across the last 3 years for performance metrics (most-recent year weighted highest). How this score is calculated →

Health score ≠ stock price. This rates the quality of Acro Biomedical Co Ltd's business: profitability, growth, balance sheet strength. It doesn't tell you whether the stock is a good buy at today's price. Not financial advice. Use it alongside valuation analysis and your own research.

Leverage

Acro Biomedical Co Ltd carries a low D/E ratio of -1.04, meaning only $-1.04 of long-term debt for every $1 of shareholders' equity. This conservative leverage earns a score of 94/100, indicating a strong balance sheet with room for future borrowing.

Liquidity

Acro Biomedical Co Ltd's current ratio of 0.04 is below the typical benchmark, resulting in a score of 0/100. This tight liquidity could limit financial flexibility if cash inflows slow.

Key Financial Metrics

Export CSV

Earnings & Revenue

Revenue

Acro Biomedical Co Ltd generated $0 in revenue in fiscal year 2025.

EBITDA

N/A

Net Income

N/A

EPS (Diluted)

$0.00

Acro Biomedical Co Ltd earned $0.00 per diluted share (EPS) in fiscal year 2025.

Cash & Balance Sheet

Free Cash Flow

N/A

Cash & Debt

$4K

YoY+760.9%

5Y CAGR-25.7%

10Y CAGR-17.3%

Acro Biomedical Co Ltd held $4K in cash against $0 in long-term debt as of fiscal year 2025.

Dividends Per Share

N/A

Shares Outstanding

60M

YoY+0.0%

5Y CAGR+4.7%

10Y CAGR+14.3%

Acro Biomedical Co Ltd had 60M shares outstanding in fiscal year 2025. This represents an increase of 0.0% from the prior year.

Margins & Returns

Gross Margin

N/A

Operating Margin

N/A

Net Margin

N/A

Return on Equity

N/A

Capital Allocation

R&D Spending

N/A

Share Buybacks

N/A

Capital Expenditures

N/A

ACBM Income Statement

Metric	FY25	FY24	FY23	FY22	FY21	FY20
Revenue	$0	$0	$0-100.0%	$659K-45.0%	$1.2M+74.1%	$688K
Cost of Revenue	N/A	N/A	$0-100.0%	$518K-44.8%	$938K+77.5%	$529K
Gross Profit	N/A	N/A	$0-100.0%	$141K-45.9%	$260K+62.8%	$159K
R&D Expenses	N/A	$0	N/A	N/A	$5.3M	N/A
SG&A Expenses	N/A	$38K	N/A	N/A	$2.7M+820.4%	$290K
Operating Income	N/A	-$38K	N/A	N/A	N/A	-$130K
Interest Expense	N/A	N/A	$3K+87.9%	$2K+91.0%	$893-16.3%	$1K
Income Tax	$0	$0	$0	$0	$0+100.0%	-$18K
Net Income	N/A	-$42K	N/A	N/A	N/A	-$117K
EPS (Diluted)	$0.00	$0.00+100.0%	$-0.15+42.3%	$-0.26	N/A	N/A

Metric	Q1'26	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24	Q2'24
Revenue	$0	N/A	$0	$0	$0	N/A	$0	$0
Cost of Revenue	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Gross Profit	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
R&D Expenses	N/A	N/A	N/A	N/A	N/A	N/A	$0	$0
SG&A Expenses	N/A	N/A	N/A	$14K+52.4%	$9K	N/A	$9K+0.2%	$9K
Operating Income	N/A	N/A	N/A	-$14K-52.4%	-$9K	N/A	-$9K-0.2%	-$9K
Interest Expense	N/A	N/A	N/A	N/A	$22K	N/A	$6K	N/A
Income Tax	N/A	N/A	$0	$0	$0	N/A	$0	$0
Net Income	N/A	N/A	N/A	-$16K-51.1%	-$10K	N/A	-$10K-0.8%	-$10K
EPS (Diluted)	$0.00	N/A	$0.00	$0.00	$0.00	N/A	$0.00	$0.00

ACBM Balance Sheet

Metric	FY25	FY24	FY23	FY22	FY21	FY20
Total Assets	$14K-55.9%	$32K-45.3%	$58K-91.5%	$687K-9.7%	$761K-23.7%	$998K
Current Assets	$14K+177.7%	$5K+212.2%	$2K-99.8%	$658K-6.9%	$706K-27.4%	$973K
Cash & Equivalents	$4K+760.9%	$476+26.6%	$376-93.6%	$6K-93.9%	$95K+425.6%	$18K
Inventory	N/A	N/A	N/A	N/A	$0-100.0%	$938K
Accounts Receivable	N/A	N/A	$0-100.0%	$639K+6.8%	$598K	$0
Goodwill	N/A	N/A	N/A	N/A	N/A	N/A
Total Liabilities	$401K+22.7%	$327K+3.6%	$315K+56.9%	$201K+71.4%	$117K-62.4%	$312K
Current Liabilities	$401K+22.7%	$327K+13.3%	$289K+43.5%	$201K+119.4%	$92K-70.6%	$312K
Long-Term Debt	N/A	N/A	N/A	N/A	N/A	N/A
Total Equity	-$387K-31.2%	-$295K-14.8%	-$257K-152.8%	$486K-24.4%	$644K-6.1%	$686K
Retained Earnings	-$32.8M-0.3%	-$32.7M-0.1%	-$32.6M-37.0%	-$23.8M-200.0%	-$7.9M-3225.5%	-$239K

Metric	Q1'26	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24	Q2'24
Total Assets	$4K-72.5%	$14K+226.1%	$4K-91.9%	$53K+111.6%	$25K-21.3%	$32K-17.3%	$39K-14.6%	$45K
Current Assets	$4K-72.5%	$14K+226.1%	$4K-89.1%	$40K+716.9%	$5K-4.4%	$5K+624.1%	$701-24.3%	$926
Cash & Equivalents	$4K-5.5%	$4K-5.2%	$4K+16526.9%	$26-89.6%	$251-47.3%	$476-32.1%	$701-24.3%	$926
Inventory	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Accounts Receivable	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Goodwill	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Total Liabilities	$431K+7.5%	$401K-8.2%	$437K+17.8%	$371K+12.7%	$329K+0.7%	$327K+0.9%	$324K+0.8%	$322K
Current Liabilities	$431K+7.5%	$401K-8.2%	$437K+17.8%	$371K+12.7%	$329K+0.7%	$327K+3.0%	$317K+3.0%	$308K
Long-Term Debt	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Total Equity	-$427K-10.4%	-$387K+10.6%	-$433K-36.2%	-$318K-4.5%	-$304K-3.0%	-$295K-3.3%	-$286K-3.3%	-$276K
Retained Earnings	-$32.8M-0.1%	-$32.8M+0.1%	-$32.8M-0.4%	-$32.7M0.0%	-$32.7M0.0%	-$32.7M0.0%	-$32.6M0.0%	-$32.6M

ACBM Cash Flow Statement

Metric	FY25	FY24	FY23	FY22	FY21	FY20
Operating Cash Flow	N/A	-$37K-137.6%	-$15K+89.5%	-$147K-149.3%	$299K+250.1%	-$199K
Capital Expenditures	N/A	N/A	N/A	N/A	N/A	N/A
Free Cash Flow	N/A	N/A	N/A	N/A	N/A	N/A
Investing Cash Flow	N/A	N/A	N/A	N/A	N/A	N/A
Financing Cash Flow	N/A	$37K+269.0%	$10K-82.8%	$58K+126.1%	-$222K-202.6%	$217K
Dividends Paid	N/A	N/A	N/A	N/A	N/A	N/A
Share Buybacks	N/A	N/A	N/A	N/A	N/A	N/A

Metric	Q1'26	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24	Q2'24
Operating Cash Flow	N/A	-$25K	N/A	-$94K-317.1%	-$23K-114.3%	-$11K-66.0%	-$6K-0.1%	-$6K
Capital Expenditures	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Free Cash Flow	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Investing Cash Flow	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Financing Cash Flow	N/A	$25K	N/A	$94K+320.3%	$22K+116.8%	$10K+68.4%	$6K-14.0%	$7K
Dividends Paid	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Share Buybacks	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

ACBM Financial Ratios

Metric	FY25	FY24	FY23	FY22	FY21	FY20
Gross Margin	N/A	N/A	N/A	21.3%-0.3pp	21.7%-1.5pp	23.2%
Operating Margin	N/A	N/A	N/A	N/A	N/A	-19.0%
Net Margin	N/A	N/A	N/A	N/A	N/A	-17.1%
Return on Equity	N/A	N/A	N/A	N/A	N/A	-17.1%
Return on Assets	N/A	-132.3%	N/A	N/A	N/A	-11.8%
Current Ratio	0.04+0.0	0.020.0	0.01-3.3	3.27-4.4	7.71+4.6	3.12
Debt-to-Equity	-1.04+0.1	-1.11+0.1	-1.23-1.6	0.41+0.2	0.18-0.3	0.46
FCF Margin	N/A	N/A	N/A	N/A	N/A	N/A

Metric	Q1'26	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24	Q2'24
Gross Margin	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Operating Margin	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Net Margin	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Return on Equity	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Return on Assets	N/A	N/A	N/A	-29.2%+11.7pp	-40.9%	N/A	-26.5%-4.1pp	-22.4%
Current Ratio	0.01-0.0	0.04+0.0	0.01-0.1	0.11+0.1	0.010.0	0.02+0.0	0.000.0	0.00
Debt-to-Equity	-1.01+0.0	-1.04-0.0	-1.01+0.2	-1.17-0.1	-1.08+0.0	-1.11+0.0	-1.14+0.0	-1.16
FCF Margin	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

Note: Shareholder equity is negative (-$387K), which causes debt-to-equity and return on equity ratios to appear negative or not meaningful. This can occur from accumulated losses or large share buyback programs.

Note: The current ratio is below 1.0 (0.04), indicating current liabilities exceed current assets, which may suggest potential short-term liquidity concerns.

Frequently Asked Questions

What is Acro Biomedical Co Ltd's annual revenue?

Acro Biomedical Co Ltd (ACBM) reported $0 in total revenue for fiscal year 2025. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.

What are Acro Biomedical Co Ltd's total assets?

Acro Biomedical Co Ltd (ACBM) had $14K in total assets as of fiscal year 2025, including both current and long-term assets.

How many shares does Acro Biomedical Co Ltd have outstanding?

Acro Biomedical Co Ltd (ACBM) had 60M shares outstanding as of fiscal year 2025.

What is Acro Biomedical Co Ltd's current ratio?

Acro Biomedical Co Ltd (ACBM) had a current ratio of 0.04 as of fiscal year 2025, which is below 1.0, which may suggest potential liquidity concerns.

What is Acro Biomedical Co Ltd's debt-to-equity ratio?

Acro Biomedical Co Ltd (ACBM) had a debt-to-equity ratio of -1.04 as of fiscal year 2025, measuring the company's financial leverage by comparing total debt to shareholder equity.

Why is Acro Biomedical Co Ltd's debt-to-equity ratio negative or unusual?

Acro Biomedical Co Ltd (ACBM) has negative shareholder equity of -$387K as of fiscal year 2025, which causes the debt-to-equity ratio to appear negative or not meaningful. This can occur when accumulated losses exceed invested capital, or after large share buyback programs. Other solvency metrics like the current ratio or interest coverage may be more informative.

How financially healthy is Acro Biomedical Co Ltd?

Acro Biomedical Co Ltd (ACBM) scores 16 out of 100 on our Financial Profile, indicating weak overall financial health. This composite score evaluates six dimensions: profitability (operating margin), revenue growth, leverage (debt-to-equity), liquidity (current ratio), cash flow quality (free cash flow margin), and shareholder returns (return on equity). Each dimension is normalized against standard financial benchmarks. Learn more in our complete guide to financial health indicators.